Table 4.

The impact of investigated miRNA polymorphisms on nausea after 21 and 28 days of tramadol treatment (N = 99)

SNP	Genotype	Nausea days N (%) 21	OR (95% CI)	P	Nausea days N (%) 28	OR (95% CI)	P
MIRrs1011784 23B	CC	9 (16.4)	Ref.		4 (7.5)	Ref.
	CG	4 (12.9)	0.76 (0.21–2.7)	0.668	5 (16.1)	2.36 (0.58–9.54)	0.230
	GG	2 (25)	1.7 (0.3–9.83)	0.551	3 (37.5)	7.35 (1.27–42.6)	0.026
	CG+GG	6 (15.4)	0.93 (0.3–2.86)	0.898	8 (20.5)	3.16 (0.88–11.39)	0.078
MIRrs2296616 107	GG	6 (31.6)	Ref.		2 (10.5)	Ref.
	GA	4 (8.9)	0.21 (0.05–0.87)	0.031	4 (8.7)	0.81 (0.14–4.84)	0.817
	AA	5 (16.7)	0.43 (0.11–1.69)	0.229	6 (21.4)	2.32 (0.41–12.96)	0.338
	GA+AA	9 (12)	0.30 (0.09–0.97)	0.045	10 (13.5)	1.33 (0.27–6.64)	0.730

N = sample size; OR = odds ratio; SNP = single nucleotide polymorphism; 95% CI = 95% confidence interval